Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates

Bibliography

• Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8:E101-11
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 2006;103:13682-7
   PubMed Web of Science ®Google Scholar
• Guengerich PF. Cataloguing the repertoire of nature's blowtorch, P450. Chem Biol 2009;16:1215-16
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P450, drugs, and diseases. Mol Intervent 2003;3:194-204
   PubMedGoogle Scholar
• Yang X, Zhang B, Molony C, Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Gen Res 2010;20:1020-36
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33
   PubMed Web of Science ®Google Scholar
• Wang MZ, Saulter JY, Usuki E, CYP4F are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-aminophenyl)furan-bis-o-methylamidoxime]. Drug Metab Dispos 2006;34:1985-94
   PubMed Web of Science ®Google Scholar
• Rushmore TH, Kong TAN. Pharmacogenomiccs, regulation and signaling pathways of phase I and phase II drug metabolizing enzymes. Cur Drug Metab 2002;3:481-90
   PubMed Web of Science ®Google Scholar
• Wang B, Sanchez RI, Franklin RB, The involvement of CYP3A4 and CYP2C9 in the metabolism of 17alpha-ethinylestradiol. Drug Metab. Disposition 2004;32:1209-12
   Google Scholar
• McGinnity DF, Tucker J, Trigg S, Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33:1700-7
   PubMed Web of Science ®Google Scholar
• O'Reilly RA, Goulart DA, Kunze KL, Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51:656-67
   PubMed Web of Science ®Google Scholar
• Segel IH. Enzyme kinetics. John Wiley and Sons New York; NY: 1975
   Google Scholar
• Rodrigues AD. Drug-drug interactions. Marcel Dekker, Inc. New York; NY: 2002
   Google Scholar
• Racha JK, Zhao ZS, Olejnik N, Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 2003;18(2):128-38
   PubMedGoogle Scholar
• Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Recommendations. U.S. Department of Health and Human Services, Food and Drug Administration. Rockville; MD: 2012
   Google Scholar
• Nomier AA, Ruegg C, Shoemaker M, Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001;29:748-53
   PubMed Web of Science ®Google Scholar
• Li AP, Lu C, Brent JA, Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chem Biol Interac 1999;121:17-35
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31
   PubMed Web of Science ®Google Scholar
• Li AP, Doshi U. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4. Drug Metab Lett 2011;5:183-91
   PubMedGoogle Scholar
• Kaneko A, Kato M, Sekiguchi N, In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica 2009;39:803-10
   PubMed Web of Science ®Google Scholar
• Lubberstedt M, Muller-Vieira U, Mayer M, HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 2011;63:59-68
   PubMed Web of Science ®Google Scholar
• Hart SN, Li Y, Nakamoto K, A Comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 2010;38:988-94
   PubMed Web of Science ®Google Scholar
• Guguen-Guillouzoa C, Corlua A, Guillouzob A. Stem cell-derived hepatocytes and their use in toxicology. Toxicology 2010;270:3-9
   PubMed Web of Science ®Google Scholar
• Li AP. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome p450 (p450) inhibitors, and p450 inducers. Drug Metab Dispos 2009;37:1598-603
   PubMed Web of Science ®Google Scholar
• Luo G, Guenther T, Gan L-S, CYP3A4 induction by xenobiotics: experimental methods and impact on drug discovery and development. Curr Drug Metab 2001;5:483-505
   Web of Science ®Google Scholar
• Donato TM, Jimenez N, Castell JV, Fluorescence based assays for screening nine cytochrome p450 (p450) activities in intact cells expressing individual human p450 enzymes. Drug Metab Dispos 2004;32:699-706
   PubMed Web of Science ®Google Scholar
• Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chem Biol Interac 2001;134:271-81
   PubMed Web of Science ®Google Scholar
• Cali JJ, Niles A, Valley MP, Bioluminescent assays for ADMET. Expert Opin Drug Metab Toxicol 2008;4:103-20
   PubMed Web of Science ®Google Scholar
• Cali JJ, Ma D, Sobol M, Luminogenic cytochrome CYP assays. Expert Opin Drug Metab Toxicol 2006;2:629-45
   PubMed Web of Science ®Google Scholar
• Doshi U, Li AP. Luciferin IPA–based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. J Biomol Screen 2011;16:903-9
   PubMed Web of Science ®Google Scholar
• Meisenheimer PL, Uyeda HT, Ma D, Proluciferin acetals as bioluminogenic substrates for cytochrome p450 activity and probes for cyp3A inhibition. Drug Metab Dispos 2011;39:2403-10
   PubMed Web of Science ®Google Scholar
• P450-Glo assay technical bulletin. Available from: http://www.promega.com/∼/media/Files/Resources/Protocols/Technical%20Bulletins/101/P450%20Glo%20Assays%20Protocol.pdf [Last accessed 22 April 2012]
   Google Scholar
• Branchini RB, Magyar RA, Murtiashaw MH, Site-directed mutagenesis of histidine 245 in firefly luciferase: model of the active site. Biochemistry 1998;37:15311-19
   PubMed Web of Science ®Google Scholar
• Sobol M, Ma D, Cali JJ. Selective Cytochrome P450 4A11 Enzyme Assay Using a Novel Bioluminescent Probe Substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/selective-cytochrome-p450-4a11-enzyme-assay-using-a-novel-bioluminescent-probe-substrate/ [Last accessed 16 January 2012]
   Google Scholar
• Cali JJ, Ma D. A Rapid Cell Based Bioluminescent CYP1A1 Aryl Hydrocarbon Receptor Activation Assay. Available from: http://www.promega.com/resources/scientific_posters/posters/a-rapid-cell-based-bioluminscent-cyp1a1-aryl-hydrocarbon-receptor-assay-poster/ [Last accessed 24 April 2012]
   Google Scholar
• Moeller T, Ma D, Dennel S, Cali J. Comparison of novel luciferin-1A2 substrate and phenacetin for measuring CYP1A2 induction in human hepatocytes. The Toxicologist 2012:110. Available from: http://www.toxicology.org/AI/PUB/Toxicologist12.pdf [Last accessed 22 April 2012]
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Branchini BR, Hayward MM, Bamford S, Naphthyl- and quinolylluciferin: green and red light emitting firefly luciferin analogues. Photochem Photobiol 1989;49:689-95
   PubMed Web of Science ®Google Scholar
• Stresser DM, Blanchard AP, Turner SD, Substrate-dependent modulation of cyp3a4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000;28:1440-8
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M. Baseline lipophilicity relationships in human cytochromes p450 associated with drug metabolism. Drug Metab Rev 2003;35:1-18
   PubMed Web of Science ®Google Scholar
• Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-36
   PubMed Web of Science ®Google Scholar
• Cali JJ, Ma D, Sobol MS, P450-Glo™ CYP2C19 and CYP2D6 assays and screening systems. Cell Notes 2006;14:20-4
   Google Scholar
• Vermeulen NPE. Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr Top Med Chem 2003;3:1227-39
   PubMed Web of Science ®Google Scholar
• Krimmer HP, Drauz K, Kleemann A. Reaction of beta-mercapto alpha-amino acids with nitriles. Chem Ztg 1987;111:357-61
   Web of Science ®Google Scholar
• Larson B, Kelts JL, Banks P, Automation and miniaturization of the bioluminescent UGT-Glo assay for screening of UDP-glucuronosyltranferase inhibition by various compounds. J Lab Automot 2011;16:38-46
   PubMedGoogle Scholar
• Francisco WA, Abu-Soud HM, Baldwin TO, Interaction of bacterial luciferase with aldehyde substrates and inhibitors. J Biol Chem 1993;268:24734-41
   PubMed Web of Science ®Google Scholar
• Vermilion JL, Coon MJ. Highly purified detergent-solubilized NADPH-cytochrome P-450 reductase from phenobarbital-induced rat liver microsomes. Biochem Biophys Res Com 1974;60:1315-22
   PubMed Web of Science ®Google Scholar
• Locuson CW, Wienkers LC, Jones JP, CYP2C9 protein interactions with cytochrome b5: effects on the coupling of catalysis. Drug Metab Dispos 2007;35:1174-81
   PubMed Web of Science ®Google Scholar
• Sobol M, Ma D, Unch J, Cali JJ. Nonselective Cytochrome P450 Enzyme Assay Using a Novel Bioluminescent Probe Substrate that Cross-Reacts with Multiple P450 Enzymes. Available from: http://www.promega.com/resources/articles/pubhub/enotes/nonselective-cyp450-assay-using-a-biolum-probe-substrate-that-cross-reacts-with-multiple-p450s/ [Last accessed 22April 2012]
   Google Scholar
• Wester MR, Yano JK, Schock GA, The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-angstrom resolution. J Biol Chem 2004;279:35630-7
   PubMed Web of Science ®Google Scholar
• Veith H, Southall N, Huang R, Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 2009;27:1050-5
   PubMed Web of Science ®Google Scholar
• Stevens JC. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 2006;11:440-5
   PubMed Web of Science ®Google Scholar
• Leeder JS, Gaedigk R, Marcucci KA, Variability of CYP3A7 expression in human fetal liver. Pharmacol Expert Ther 2005;314:626-35
   PubMed Web of Science ®Google Scholar
• Sobol MS, Ma D, Cali JJ. Selective cytochrome p450 3A7 enzyme assay using a novel bioluminescent probe substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/selective-cytochrome-p450-3a7-enzyme-assay-using-a-novel-bioluminescent-probe-substrate/ [Last accessed 16 January 2012]
   Google Scholar
• Enayetallah AE, French RA, Thibodeau MS, Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. Histochem Cytochem 2004;52(4):447-54
   PubMed Web of Science ®Google Scholar
• Chen Y, Ferguson SS, Negishi M, Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor. J Pharm Expert Ther 2004;308:495-501
   PubMed Web of Science ®Google Scholar
• Earley S, Patuszyn A, Walker BR. Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol 2003;285:H127-36
   PubMed Web of Science ®Google Scholar
• Granville DJ, Tashakkor B, Takeuchi C, Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Nat Acad Sci USA 2003;101:1321-6
   Web of Science ®Google Scholar
• Ma Q, Lu AYH. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35:1009-16
   PubMed Web of Science ®Google Scholar
• Brosen K, Skjelbo E, Rasmussen BB, Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;1211-14
   PubMed Web of Science ®Google Scholar
• Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochrome P450 1A1 and 1B1. Cancer Sci 2004;95:1-6
   PubMed Web of Science ®Google Scholar
• Shimada T, Gillam EMJ, Sutter TR, Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug MEtab Dispos 1997;29:617-22
   Google Scholar
• Hu W, Sorrentino C, Denison MS, Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro, Mol Pharmacol. 2007;71:1475-86
   Google Scholar
• Zhang Z-Y, Pelletier RD, Wong YN, Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary hepatocytes versus transformed human cells. Biochem Biophys Res Commun 2006;341:399-407
   PubMed Web of Science ®Google Scholar
• Sobol M, Ma D, Woodroofe CC, Cytochrome P450 4F2 and 4F3B enzyme assays using a novel bioluminescent probe substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/cytochrome-p450-4f2-and-4f3b-enzyme-assays-using-a-novel-bioluminescent-probe-substrate/ [Last accessed 16 January 2012]
   Google Scholar
• Sobol M, Ma D, Cali JJ. Cytochrome P450 4F12 Enzyme Assay Using a Novel Bioluminescent Probe Substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/cytochrome-p450-4f12-enzyme-assay-using-a-novel-bioluminescent-probe-substrate/ [Last accessed 16 January 2012]
   Google Scholar
• Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 2002;13:273-83
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Mise M, Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharm Expert Ther 2002;300:298-304
   PubMed Web of Science ®Google Scholar
• Johnson EF, Hsu M-H, Sava U, Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 2002;181-182:203-6
   PubMed Web of Science ®Google Scholar
• Aoyama T, Hardwick JP, Imaoka S, Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the omega- and (omega-1)-hydroxylation of fatty acids and the omega-hydroxylation of prostaglandins E1 and F2alpha.. J Lipd Res 1990;31:1477-82
   PubMed Web of Science ®Google Scholar
• Meisenheimer PL, O'Brien MA, Cali JJ. Luminogenic substrates: the basis for a new paradigm in assay design. Available from: http://www.promega.com/∼/media/Files/Resources/Cell%20Notes/cn022/Luminogenic%20Substrates-%20The%20Basis%20for%20a%20New%20Paradigm%20in%20Assay%20Design.ashx [Last accessed 2 April 2012]
   Google Scholar
• Molinspiration molecular properties calculator. Available from: http://www.molinspiration.com/cgi-bin/properties [Last accessed 17 January 2012]
   Google Scholar
• Ma D, Sobol M, Woodroofe CC, Cali JJ. Cytochrome P450 2J2 enzyme assay using a novel bioluminescent probe substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/cytochrome-p450-2j2-enzyme-assay-using-a-novel-bioluminescent-probe-substrate/ [Last accessed 22 April 2012]
   Google Scholar
• RCSB Protein Data Bank entry 1R90. Available from: http://www.rcsb.org/pdb/explore/explore.do?structureId=1R9O [Last accessed 14 May 2012]
   Google Scholar